Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
Phase 2
Completed
- Conditions
- Warts
- Interventions
- Biological: Candida antigen
- Registration Number
- NCT04399577
- Lead Sponsor
- Zagazig University
- Brief Summary
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
- Detailed Description
39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- Chronic multiple cutaneous
Exclusion Criteria
- Hypersensitivity to Candida antigen
- Fever
- Immunosuppressive disorders
- Previous wart therapy in the last month
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Wart Patients Candida antigen Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
- Primary Outcome Measures
Name Time Method Resolution of warts 12 weeks 100% clearance of warts
- Secondary Outcome Measures
Name Time Method Recurrence 6 months Reappearance of warts
Trial Locations
- Locations (1)
Zagazig University Faculty of Medicine
🇪🇬Zagazig, Sharqia, Egypt